Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Peggs

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|March 15, 2003
Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemiaKarl Peggs, Stephen Mackinnon
Expert Opinion on Biological Therapy|November 30, 2020
Cell therapy for cytomegalovirus infectionLorna Neill, Karl Peggs
British Journal of Hospital Medicine (London, England : 2005)|August 10, 2012
Life after allogeneic bone marrow transplantCatherine Hockings, Karl Peggs
Blood Cells, Molecules & Diseases|September 18, 2007
Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cellsStephen Mackinnon, Kirsty Thomson, Stephanie Verfuerth, et al.
Blood|January 5, 2002
Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cellsKarl Peggs, Stephanie Verfuerth, Arnold Pizzey, et al.
Cytotherapy|March 18, 2014
Immunotherapy: opportunities, risks and future perspectivesMartin Hildebrandt, Karl Peggs, Lutz Uharek, et al.
British Journal of Haematology|March 21, 2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCLSally Moore, Irfan Kayani, Karl Peggs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantationJulio Delgado, Nichola Cooper, Kirsty Thomson, et al.
British Journal of Haematology|May 8, 2013
Management of cytomegalovirus infection in haemopoietic stem cell transplantationVincent Emery, Mark Zuckerman, Graham Jackson, et al.
British Journal of Haematology|August 19, 2011
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapySally Moore, Karl Peggs, Kirsty Thomson, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|March 15, 2003
Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemiaKarl Peggs, Stephen Mackinnon
Expert Opinion on Biological Therapy|November 30, 2020
Cell therapy for cytomegalovirus infectionLorna Neill, Karl Peggs
British Journal of Hospital Medicine (London, England : 2005)|August 10, 2012
Life after allogeneic bone marrow transplantCatherine Hockings, Karl Peggs
Blood Cells, Molecules & Diseases|September 18, 2007
Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cellsStephen Mackinnon, Kirsty Thomson, Stephanie Verfuerth, et al.
Blood|January 5, 2002
Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cellsKarl Peggs, Stephanie Verfuerth, Arnold Pizzey, et al.
Cytotherapy|March 18, 2014
Immunotherapy: opportunities, risks and future perspectivesMartin Hildebrandt, Karl Peggs, Lutz Uharek, et al.
British Journal of Haematology|March 21, 2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCLSally Moore, Irfan Kayani, Karl Peggs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantationJulio Delgado, Nichola Cooper, Kirsty Thomson, et al.
British Journal of Haematology|May 8, 2013
Management of cytomegalovirus infection in haemopoietic stem cell transplantationVincent Emery, Mark Zuckerman, Graham Jackson, et al.
British Journal of Haematology|August 19, 2011
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapySally Moore, Karl Peggs, Kirsty Thomson, et al.
Pageof 4